awmsg logo



elvitegravir/cobicistat/emtricitabine/tenofovir (Stribild®)


Reference No. 1446

Publication date:
03/12/2013


Last review date:
01/12/2016

Appraisal information

elvitegravir/cobicistat/emtricitabine/tenofovir (Stribild®) 150 mg/150 mg/200 mg/245 mg film-coated tablet


Company: Gilead Sciences Ltd
BNF category: Infections
NMG meeting date: 11/09/2013
AWMSG meeting date: 16/10/2013
   
   
Submission Type: Full Submission
Status: Recommended
Advice No: 2413
Ministerial ratification: 02/12/2013

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (Stribild®) is recommended as an option for use within NHS Wales for the treatment of human immunodeficiency virus-1 (HIV 1) infection in adults aged 18 years and over who are antiretroviral-treatment-naive or are infected with HIV-1 without known mutations associated with resistance to any of the three antiretroviral agents in Stribild®. This recommendation applies only in circumstances where the approved Wales Patient Access Scheme is utilised.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download